{"prompt": "['Protocol', 'ALXN1210-MG-306 Amendment 2', '4.1.4.', 'Open-Label Extension Period', 'After the 26-Week Randomized-Controlled Period and assessments on Day 183 (Week 26),', 'patients in the placebo group will receive a blinded loading dose of ravulizumab and patients in', 'the ravulizumab group will receive a blinded ravulizumab dose of 900 mg; the 900-mg dose was', 'chosen to ensure maintenance of complete C5 inhibition until the next scheduled maintenance', 'dose at Week 28 (Day 197). Starting at Week 28, all patients will begin open-label ravulizumab', 'maintenance doses q8w.', 'The OLE Period for each patient will commence when the patient receives a dose of ravulizumab', 'on Week 26 (Day 183) and will continue for up to 2 years or until the product is registered or', 'approved (in accordance with country-specific regulations), whichever occurs first.', '4.2.', 'Standard Protocol Definitions', '4.2.1.', 'Clinical Deterioration', 'For this protocol, Clinical Deterioration is defined as any of the following:', '1. Patients who experience an MG Crisis, which is defined as weakness from MG that is severe', 'enough to necessitate intubation or to delay extubation following surgery. The respiratory', 'failure is due to weakness of respiratory muscles. Severe bulbar (oropharyngeal) muscle', 'weakness often accompanies the respiratory muscle weakness, or may be the predominant', 'feature in some patients; or,', '2. Significant symptomatic worsening to a score of 3 or a 2-point worsening from Baseline on', 'any one of the individual MG-Activities of Daily Living (MG-ADL) items other than double', 'vision or eyelid droop; or,', '3. Administration of rescue therapy to a patient whose, in the opinion of the Investigator or', 'Investigator-designated physician, health would be in jeopardy, if rescue therapy were not', 'given (eg, emergent situations).', '4.2.2.', 'Unscheduled Visits', 'Under exceptional circumstances, additional (unscheduled) visits outside the specified visits are', 'permitted at the discretion of the Investigator. Procedures, tests, and assessments will be', 'performed at the discretion of the Investigator and efforts will be made to map the corresponding', 'data to the appropriate visit as described in the electronic case report form (eCRF) completion', 'guidelines and training materials.', '4.2.3.', 'Properly Trained Clinical Evaluator', 'Properly Trained Clinical Evaluators are study staff that have been certified in administering the', 'MG-ADL, QMG, and Myasthenia Gravis Composite (MGC) assessments. Only Properly', 'Trained Clinical Evaluators may administer these assessments. A Properly Trained Clinical', 'Evaluator may be a neurologist, physical therapist, or other study team member delegated by the', 'Investigator. Only the Investigator or a neurologist may perform the manual muscle test (MMT),', 'components of the MGC, the Myasthenia Gravis Foundation of America-Post-Interventional', 'Status (MGFA-PIS), and Myasthenia Gravis Foundation of America (MGFA) Classification.', 'Page 33 of 109', 'Alexion Confidential']['Protocol', 'ALXN1210-MG-306 Amendment 2', 'Clinical Evaluator training and certification for this protocol will take place either at the', \"Investigator's Meeting or via the Sponsor's designated on-line training portal.\", '4.2.4.', 'Responsibilities for Myasthenia Gravis Assessments', 'Responsibilities for MG assessments are listed in Table 3. Throughout the study, MG', 'assessments should be performed at approximately the same time of day by a Properly Trained', 'Clinical Evaluator, and preferably the same evaluator. The MG-ADL should always be', 'performed first, followed by the QMG.', 'Table 3:', 'Myasthenia Gravis Assessments and Responsibilities', 'Assessment', 'Evaluator', 'MG-ADL', 'Properly Trained Clinical Evaluator', 'QMG', 'Properly Trained Clinical Evaluator', 'MGC', 'Properly Trained Clinical Evaluator', 'MGC (MMT Components)', 'Investigator or Neurologist', 'MGFA-PIS (modified version)', 'Investigator or Neurologist', 'MGFA Classification', 'Investigator or Neurologist', 'Abbreviations: MG-ADL = Myasthenia Gravis Activities of Daily Living Profile; MGC = Myasthenia Gravis', 'Composite scale; MGFA = Myasthenia Gravis Foundation of America; MGFA-PIS = Myasthenia Gravis', 'Foundation of America Post-Intervention Status; MMT = manual muscle test; QMG = Quantitative Myasthenia', 'Gravis score for disease severity.', '4.3.', 'Scientific Rationale for Study Design', 'Published data support the MG-ADL profile as an established, sensitive, and objective', 'assessment of treatment response over time in patients with gMG (Howard, 2017).', 'The safety parameters being evaluated are commonly used in clinical studies per International', 'Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use', '(ICH) and Good Clinical Practice (GCP) guidance.', 'Placebo was selected as the control and patients will be allowed to continue stable therapy with', 'standard of care therapy (ie, ISTs) throughout the course of the study, which thereby allows for', 'comparison of the safety and efficacy of ravulizumab when administered in addition to the', \"patient's standard of care treatment to current standard of care therapies in patients with gMG.\", 'Given the heterogeneity of the disease and fluctuation in the severity of symptoms, there is no', '1 international standard of care accepted, and targeted treatment with complement-inhibitor', 'drugs, such as the recently introduced eculizumab, is not yet widely available to patients', 'worldwide and is not yet considered standard of care for all patients with gMG. A', 'placebo-controlled study allows for the evaluation of treatment effect and allows for a', 'double-blind design; an important study condition to be maintained when considering endpoints', 'that includes neurological scales, which are known to be especially prone to placebo effects. The', 'placebo-controlled part of the study will be limited to 26 weeks, after which time all patients will', 'transition to open-label treatment with ravulizumab for up to 2 years during the OLE Period. At', 'all points throughout the study, physicians will be encouraged to prioritize patient safety, and if', 'patients experience Clinical Deterioration, the full range of rescue therapies will be permitted.', 'Page 34 of 109', 'Alexion Confidential']\n\n###\n\n", "completion": "END"}